A proposal for a simple and inexpensive therapeutic cancer vaccine

Immunology and Cell Biology

Volumn 90, Issue 3, 2012, Pages 310-313

  Fahrer, Aude M ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

cancer immunotherapy; cancer therapeutic; cancer vaccine; Coley's toxin; Complete Freund's Adjuvant

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CANCER VACCINE; COLEY'S TOXIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; FREUND ADJUVANT; INTERLEUKIN 10 ANTIBODY; IPILIMUMAB; MYCOBACTERIUM EXTRACT; PROGRAMMED DEATH 1 RECEPTOR; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR EXTRACT; TUMOR EXTRACT PLUS FREUND ADJUVANT; UNCLASSIFIED DRUG;

ABSCESS; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA; CELL ACTIVATION; CELL FUNCTION; CELLULAR IMMUNITY; CHEMOTAXIS; COLON CARCINOMA; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DENDRITIC CELL ACTIVATION; DRUG COST; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GYNECOLOGIC CANCER; HUMAN; INFECTION; INJECTION SITE PAIN; INJECTION SITE ULCER; INOPERABLE CANCER; LIMB SWELLING; LUNG CANCER; MELANOMA; MYCOBACTERIUM BOVIS; MYCOBACTERIUM VACCAE; NEOPLASM; NEUROFIBROSARCOMA; NONHUMAN; PAIN; PATIENT SELECTION; SARCOMA; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION; VULVA CARCINOMA;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FREUND'S ADJUVANT; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEOPLASMS;

EID: 84858705623     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.42     Document Type: Conference Paper

References (36)

1. Folkman J, Kalluri R. Cancer without disease. Nature 2004; 427: 787. (Pubitemid 38297724)
2. Prestwich RJ, Errington F, Hatfield P, Merrick AE, Ilett EJ, Selby PJ et al. The immune system-is it relevant to cancer development, progression and treatment? Clin Oncol 2008; 20: 101-112. (Pubitemid 351194288)
3. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-727. (Pubitemid 44453458)
4. Teng MWL, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: An equilibrium with cancer. J Leukoc Biol 2008; 84: 988-993.
5. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299-308. (Pubitemid 351430867)
6. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM et al. Idiotypepulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 2002; 99: 1517-1526. (Pubitemid 34533020)
7. O'Rourke MG, Johnson MK, Lanagan CM, See JL, O'Connor LE, Slater GJ et al. Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res 2007; 17: 316-322. (Pubitemid 47462224)
8. O'Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003; 52: 387-395. (Pubitemid 36693759)
9. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-426. (Pubitemid 47509552)
10. Zanoni I, Granucci F. Regulation of antigen uptake, migration, and lifespan of dendritic cell by Toll-like receptors. J Mol Med 2010; 88: 873-880.
11. Freund J. The mode of action of immunologic adjuvants. Adv Tuberc Res 1956; 7: 130-148.
12. Andrews DM, Maraskovsky E, Smyth MJ. Cancer vaccines for established cancer: how to make them better? Immunol Rev 2008; 222: 242-255. (Pubitemid 351430374)
13. Hoption Cann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: A place in history or in the future. Postgrad Med J 2003; 79: 672-680. (Pubitemid 38134682)
14. Hoption Cann SA, van Netten JP, van Netten C, Glover DW. Spontaneous regression: A hidden treasure buried in time. Med Hypotheses 2002; 58: 115-119. (Pubitemid 34174418)
15. Coley WB. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the streptococcus erysipelas and the bacillus prodigiosus). Proc R Soc Med (Surg Sect) 1910; 3: 1-48.
16. Nauts HC, Swift WE, Coley BL. The treatment of malignant tumors by bacterial toxins as developed by the Late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res 1946; 6: 205-216.
17. Starnes CO. Coley's toxins in perspective. Nature 1992; 357: 11-12.
18. Nauts HC, McLaren JR. Coley toxins-the first century. Adv Exp Med Biol 1990; 267: 483-500.
19. Hersh EM, Gutterman JU, Mavligit GM. BCG as adjuvant immunotherapy for neoplasia. Annu Rev Med 1977; 28: 489-515.
20. Gontero P, Bohle A, Malmstrom P-U, O'Donnell MA, Oderda M, Sylvester R et al. The role of bacillus Calmette-Gué rin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010; 57: 410-429.
21. Azuma I, Seya T. Development of immunoadjuvants for immunotherapy of cancer. Int Immunopharmacol 2001; 1: 1249-1259. (Pubitemid 32522979)
22. Grange JM, Bottasso O, Stanford CA, Stanford JL. The use of mycobacterial adjuvantbased agents for immunotherapy of cancer. Vaccine 2008; 26: 4984-4990.
23. Chapel HM, August PJ. Report of nine cases of accidental injury to man with Freund's complete adjuvant. Clin Exp Immunol 1976; 24: 538-541.
24. Freund J, Thomson KJ. A simple, rapid technic of preparing water-in-oil emulsions of penicillin, drugs and biologics. Science 1945; 101: 468-469.
25. Miller LH, Saul A, Mahanty S. Revisiting Freund's incomplete adjuvant for vaccines in the developing world. Trends Parasitol 2005; 21: 412-414. (Pubitemid 41116716)
26. Graham JB, Graham RM. Autogenous vaccine in cancer patients. Surg Gynecol Obstet 1962; 114: 1-4.
27. Hughes LE, Kearney R, Tully M. A study in clinical cancer immunotherapy. Cancer 1970; 26: 269-278.
28. Hollinshead A, Arlen M, Yonemoto R, Cohen M, Tanner K, Kundin WD et al. Pilot studies using melanoma tumor-associated antigens (TAA) in specific-active immunochemotherapy of malignant melanoma. Cancer 1982; 49: 1387-1404. (Pubitemid 12143061)
29. Hollinshead A. Active specific immunotherapy and immunochemotherapy in the treatment of lung and colon cancer. Semin Surg Oncol 1991; 7: 199-210.
30. Hollinshead A, Elias EG, Arlen M, Buda B, Mosley M, Scherrer J. Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial. Cancer 1985; 56: 480-489. (Pubitemid 15035573)
31. Hollinshead A, Stewart TH, Takita H, Dalbow M, Concannon J. Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens. Cancer 1987; 60: 1249-1262. (Pubitemid 17152903)
32. Takita H, Hollinshead AC, Adler RH, Bhayana J, Ramundo M, Moskowitz R et al. Adjuvant, specific, active immunotherapy for resectable squamous cell lung carcinoma: A 5-year survival analysis. J Surg Oncol 1991; 46: 9-14.
33. Stewart TH, Hollinshead AC, Harris JE, Belanger R, Crepeau A, Hooper GD et al. Immunochemotherapy of lung cancer. Ann NY Acad Sci 1976; 277: 436-466.
34. Billiau A, Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001; 70: 849-860. (Pubitemid 33151123)
35. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory Tcell-mediated CD8 tolerance. Nat Immunol 2004; 5: 508-515. (Pubitemid 38660463)
36. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008; 222: 357-368. (Pubitemid 351430366)